{"id":"W3198880734","doi":"10.1038/s41408-021-00544-x","title":"A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)","year":2021,"lang":"en","type":"letter","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences North","funders":"Singapore General Hospital; National University of Singapore; Onyx Pharmaceuticals; Duke-NUS Medical School","keywords":"Carfilzomib; Dexamethasone; Medicine; Cyclophosphamide; Internal medicine; Phase (matter); Oncology; Intensive care medicine; Chemotherapy; Lenalidomide; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002277623,0.000694385,0.001679705,0.0003352361,0.0003030972,0.0001031129,0.0001705505,0.0003993125,0.0002104357],"category_scores_gemma":[0.00006161525,0.0004454808,0.0002980271,0.0002079659,0.0001093965,0.00008883278,0.00002929691,0.001553012,0.00000124889],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003000964,"about_ca_system_score_gemma":0.0013018,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0111205,"about_ca_topic_score_gemma":0.001611044,"domain_scores_codex":[0.9965762,0.0002317644,0.0006324571,0.0007238435,0.0009903202,0.0008453755],"domain_scores_gemma":[0.9976944,0.0003152429,0.0005476124,0.0004845366,0.000498633,0.0004595178],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.08208594,0.05275189,0.2351459,0.004235024,0.1131939,0.1657841,0.01030516,0.00009008663,0.004000316,0.000006381589,0.2300715,0.1023298],"study_design_scores_gemma":[0.5997918,0.1507479,0.02325574,0.004479629,0.04461193,0.0133451,0.002225896,0.00002576282,0.04690987,0.00009647275,0.112845,0.00166501],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9393846,0.03434584,0.0000506293,0.02147835,0.0002148335,0.002895281,0.001552678,0.00002665208,0.00005111876],"genre_scores_gemma":[0.8770474,0.07297055,0.007260112,0.01758287,0.008225014,0.002336751,0.001578677,0.0004226282,0.01257599],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5177058,"threshold_uncertainty_score":0.9997997,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02598774815005948,"score_gpt":0.3327062772657641,"score_spread":0.3067185291157046,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}